Accidentally ASCENDing Into Comparative Effective Research for Inflammatory Bowel Disease

被引：5

作者：

Siegel, Corey A. ^{[1
]}

机构：

[1] Dartmouth Hitchcock Med Ctr, Sect Gastroenterol & Hepatol, Ctr Inflammatory Bowel Dis, Lebanon, NH 03756 USA

来源：

GASTROENTEROLOGY | 2009年 / 137卷 / 06期

关键词：

ACTIVE ULCERATIVE-COLITIS; RELEASE ORAL MESALAMINE; CROHNS-DISEASE; COST-EFFECTIVENESS; MAINTENANCE; IMMUNOSUPPRESSION; ADALIMUMAB; MANAGEMENT; THERAPY;

D O I：

10.1053/j.gastro.2009.10.014

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

页码：1880 / 1882

页数：3

共 18 条

[1] Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease:: an open randomised trial [J].

D'Haens, Geert ;

Baert, Filip ;

van Assche, Gert ;

Caenepeel, Philip ;

Vergauwe, Philippe ;

Tuynman, Hans ;

De Vos, Martine ;

van Deventer, Sander ;

Stitt, Larry ;

Donner, Allan ;

Vermeire, Severine ;

Van De Mierop, Frank J. ;

Coche, Jean-Charles R. ;

van der Woude, Janneke ;

Ochsenkuehn, Thomas ;

van Bodegraven, Ad A. ;

van Hootegem, Philippe P. ;

Lambrecht, Guy L. ;

Mana, Fazia ;

Rutgeerts, Paul ;

Feagan, Brian G. ;

Hommes, Daniel .

LANCET, 2008, 371 (9613) :660-667

[2]

DORN SD, 2009, CLIN GASTROENTE 0722

[3] A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine [J].

Dubinsky, MC ;

Reyes, E ;

Ofman, J ;

Chiou, CF ;

Wade, S ;

Sandborn, WJ .

AMERICAN JOURNAL OF GASTROENTEROLOGY, 2005, 100 (10) :2239-2247

[4] Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: The ASCEND II trial [J].

Hanauer, SB ;

Sandborn, WJ ;

Kornbluth, A ;

Katz, S ;

Safdi, M ;

Woogen, S ;

Regalli, G ;

Yeh, C ;

Smith-Hall, N ;

Ajayi, F .

AMERICAN JOURNAL OF GASTROENTEROLOGY, 2005, 100 (11) :2478-2485

[5] Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared with 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial [J].

Hanauer, Stephen B. ;

Sandborn, William J. ;

Dallaire, Christian ;

Archambault, Andre ;

Yacyshyn, Bruce ;

Yeh, Chyon ;

Smith-Hall, Nancy .

CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2007, 21 (12) :827-834

[6] Once-daily, high-concentration MMX mesalamine in active ulcerative colitis [J].

Kamm, Michael A. ;

Sandborn, William J. ;

Gassull, Miguel ;

Schreiber, Stefan ;

Jackowski, Lechoslaw ;

Butler, Todd ;

Lyne, Andrew ;

Stephenson, David ;

Palmen, Mary ;

Joseph, Raymond E. .

GASTROENTEROLOGY, 2007, 132 (01) :66-75

[7] Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn's disease: a cost-effectiveness analysis [J].

Kaplan, G. G. ;

Hur, C. ;

Korzenik, J. ;

Sands, B. E. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2007, 26 (11-12) :1509-1520

[8] Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn's disease [J].

Loftus, Edward V., Jr. ;

Johnson, Scott J. ;

Yu, Andrew P. ;

Wu, Eric Q. ;

Chao, Jingdong ;

Mulani, Parvez M. .

EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2009, 21 (11) :1302-1309

[9] Rethinking Randomized Clinical Trials for Comparative Effectiveness Research: The Need for Transformational Change [J].

Luce, Bryan R. ;

Kramer, Judith M. ;

Goodman, Steven N. ;

Connor, Jason T. ;

Tunis, Sean ;

Whicher, Danielle ;

Schwartz, J. Sanford .

ANNALS OF INTERNAL MEDICINE, 2009, 151 (03) :206-W45

[10] Medical decision analysis for the management of unifocal, flat, low-grade dysplasia in ulcerative colitis [J].

Nguyen, Geoffrey C. ;

Frick, Kevin D. ;

Dassopoulos, Themistocles .

GASTROINTESTINAL ENDOSCOPY, 2009, 69 (07) :1299-1310

← 1 2 →